



Pharmaceutical Exports Post-Sigachi Industrial Accident

Posted On: 27 MAR 2026 4:25PM by PIB Delhi

While the Sigachi Industries explosion in Telangana has caused a localised disruption, India's overall export of pharmaceutical products remain resilient. India's exports of pharmaceuticals increased from USD 27.75 billion in the Calendar Year 2024 to USD 30.45 billion in the Calendar Year 2025, reflecting a growth of approximately 9.7%, indicating a steady expansion in India's pharmaceutical export performance.

The Government, through the Central Drugs Standard Control Organisation and State licensing authorities, continues to enforce good manufacturing practices to ensure quality and safety of Indian pharmaceutical products.

The Government engages in regular bilateral trade discussions through various forums including Joint Working Groups, Fast Track Mechanisms, Joint Commission Meetings and Joint Trade Committees, to ensure sustained market access, broad economic security and supply chain resilience. These dialogues serve to address trade-related queries and prevent unilateral actions or non-tariff barriers, and ensure that isolated industrial incidents do not adversely affect overall trade flows.

The Government including the export promotion agencies and Indian Missions abroad coordinate whenever concerns regarding safety or compliance are raised and facilitate the necessary exchange of information and compliance documents from exporters to address such queries/concerns effectively.

All factories are legally required to comply with safety provisions under the Occupational Safety, Health and Working Conditions Code, 2020. In order to reinforce compliance, safety awareness programmes, training of safety officers and special inspection, drives are undertaken to ensure adherence to prescribed safety protocols on a continuous basis.

This information was given by Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in a written reply in the Lok Sabha today.

PC/PM